Tag Archives: Nektar Therapeutics

November, 2018

7 November
Nektar and Pfizer Collaborate to Evaluate Combination of NKTR-214 with Avelumab and Talazoparib or Enzalutamide in Multiple Cancers

SAN FRANCISCO, Nov. 6, 2018 /PRNewswire/ — Nektar Therapeutics (NASDAQ:NKTR) announced that it has entered into an oncology clinical collaboration with Pfizer Inc. (NYSE:PFE) to evaluate several combination regimens in multiple cancer settings, including metastatic castration-resistant prostate cancer (mCRPC) and squamous cell carcinoma of the head and neck (SCCHN). The collaboration will evaluate Nektar’s lead immuno-oncology …
Share

31 May
Syndax and Nektar Therapeutics Partner for Immuno-Oncology Clinical Trial

WALTHAM, Mass. and SAN FRANCISCO, May 30, 2018 /PRNewswire/ — Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, and Nektar Therapeutics (Nasdaq: NKTR) today announced a non-exclusive, clinical collaboration to evaluate the safety and efficacy of Nektar’s NKTR-214, a CD122-biased agonist, …
Share

25 April
Nektar and Takeda Collaborate to Evaluate Potential Clinical Benefits of Two Novel and Complementary Immuno-Oncology Mechanisms

SAN FRANCISCO, April 24, 2018 /PRNewswire/ — Nektar Therapeutics (NASDAQ: NKTR) announced today that it has entered into a new clinical collaboration with Takeda Pharmaceutical Company Limited to evaluate Nektar’s investigational medicine, NKTR-214, with Takeda’s investigational medicine, TAK-659, as a potential combination treatment regimen in multiple cancer settings. NKTR-214 is …
Share

24 July
Lilly Partners with Nektar for Development of its Autoimmune Candidate NKTR-358

INDIANAPOLIS and SAN FRANCISCO, July 24, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Nektar Therapeutics (NASDAQ: NKTR) have announced a strategic collaboration to co-develop NKTR-358, a novel immunological therapy discovered by Nektar. NKTR-358, which achieved first human dose in Phase 1 clinical development in March of 2017, …
Share

22 May
Nektar and Takeda Enter Research Deal Exploring Combination Cancer Therapy Approaches

SAN FRANCISCO, May 22, 2017 /PRNewswire/ — Nektar Therapeutics (NASDAQ: NKTR) announced today that Takeda Pharmaceutical Company Limited (TSE: 4502) and Nektar have entered into a research collaboration to explore the combination of Nektar’s lead immuno-oncology candidate, the CD122-biased agonist NKTR-214, with five oncology compounds from Takeda’s cancer portfolio. The …
Share

18 March
Nektar’s Breast Cancer Drug Fails its Late-Stage Trial

Nektar Therapeutics’ experimental breast cancer drug, and key to the company’s future growth, failed a late-stage study. The company said that its NKTR-102 failed to meet its primary endpoint in the Phase III BEACON study. The drug is considered key to the Nektar’s future growth. The company’s CEO Howard Robin …
Share